July 20, 2016
Eisai said on July 19 that its California-based licensing partner Arena Pharmaceuticals has obtained the US FDA’s nod for Belviq XR (lorcaserin), a once-daily formulation of the antiobesity treatment Belviq. Belviq XR is a sustained release version of Belviq, which...read more